在接受降低剂量治疗方案的老年患者中,埃多克萨班的真实度
Sung-Chun Tang1, Shin-Yi Lin2,3, Chih-Hao Chen1
1Stroke Center and Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan.
Clinical pharmacology and therapeutics
|November 17, 2025
概括
低度的埃多克萨班会增加心房患者中风的风险. 15毫克的疗法可能会导致暴露不足,特别是在符合ELDERCARE-AF条件的个体中,肌素清除率较高.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 临床药房 临床药房
背景情况:
- 埃多克萨班是一种用于心房动 (AF) 的抗凝剂.
- 现实世界的药物度可能与试验数据有很大差异.
- 优化edoxaban的剂量对于AF患者的疗效和安全至关重要.
研究的目的:
- 为了研究AF患者的现实世界EDOXABAN度.
- 为了比较低谷度与治疗范围 (12-43 ng/mL).
- 评估埃多克萨班度与临床结果之间的关联,特别是在符合ELDERCARE-AF试验条件的患者中.
主要方法:
- 对402名接受edoxaban治疗的AF患者进行前性观察性研究.
- 测量最低埃多克萨班度,并与治疗范围进行比较.
- 收集关于缺血性中风,全身血栓栓塞 (SSE) 和重大出血的数据.
主要成果:
- 低埃多克萨班度与增加的SSE风险显著相关 (aHR,4.13).
- 在符合ELDERCARE-AF条件的患者中,与30mg疗法相比,15mg疗法与显著较低的度相关 (aOR,7.65).
- 较高的肌素清除率 (CrCL) 和较低的CHA2DS2-VA得分也与该亚组的低度有关. 在15毫克疗程中,CRCL> 50毫升/分钟的患者的暴露不足概率高于50%.
结论:
- 低埃多克萨班度与血栓栓塞事件的风险增加有关.
- 15毫克埃多克萨班治疗方案与符合ELDERCARE-AF条件的患者暴露不足的可能性更高,特别是当CrCL超过50毫升/分钟时.
- 这表明,在特定患者群体中,低剂量edoxaban治疗方案可能会带来潜在的治疗挑战.
相关概念视频
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
221
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
221
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
188
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
188
01:15Drug Dosing: Geriatric Patients
215
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
215
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
226
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
226
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K